AstraZeneca’s Imfinzi-tarlatamab combination cuts death risk 58% in Phase III lung cancer trial
AZN•AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab-dlle cut the risk of death by 58% versus Imfinzi alone in the Phase III DeLLphi-305 trial. The first-line maintenance treatment also delayed disease progression; severe treatment-related adverse events were more common, with no treatment-related deaths.
1. Trial results
The combination improved survival versus Imfinzi alone in patients with extensive-stage small cell lung cancer whose disease had not progressed after initial chemoimmunotherapy. Results will be presented at the ESMO Congress 2026 in Madrid and were published in The New England Journal of Medicine.
Related News
Johnson & Johnson's Erleada plus ADT cuts prostate cancer recurrence or death risk 62% versus surgery alone
JNJ•
Amgen drug combined with immunotherapy extends survival in lung cancer trial
AMGN•
